ETF Holdings Breakdown of HALO

Stock NameHalozyme Therapeutics Inc
TickerHALO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS40637H1095
LEI529900242I3SV9AGM753

News associated with HALO

Halozyme Therapeutics Reaches Analyst Target Price
In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgra - 2025-05-08 12:19:58
Hsbc Holdings PLC Acquires 3,289 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 52.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,615 shares of the biopharmaceutical company’s stock after purchasing an additional 3,289 shares during the quarter. Hsbc […] - 2025-05-08 08:10:47
Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High After Strong Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The company traded as high as $69.07 and last traded at $68.06, with a volume of 1856311 shares trading hands. The stock had previously closed at $59.38. The […] - 2025-05-08 06:08:54
4,426 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by Marshall Wace LLP
Marshall Wace LLP bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,426 shares of the biopharmaceutical company’s stock, valued at approximately $212,000. Other institutional investors and hedge funds have also made changes to their positions in the company. Heck […] - 2025-05-06 07:30:49
Halozyme Files Patent Infringement Lawsuit Against Merck
(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck's cancer medicine, Keytruda, infringes multiple patents that Halozyme filed - 2025-04-24 13:08:04
Legal & General Group Plc Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Legal & General Group Plc lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 225,427 shares of the biopharmaceutical company’s stock after selling 3,197 shares during the quarter. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $10,778,000 […] - 2025-04-17 09:08:53
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
CIBC Private Wealth Group LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,053 shares of the biopharmaceutical company’s stock after selling 963,451 shares during […] - 2025-04-08 08:22:55
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
California Public Employees Retirement System cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,687 shares of the biopharmaceutical company’s stock after selling 15,172 shares during the quarter. […] - 2025-04-07 08:56:55
Schroder Investment Management Group Sells 9,933,836 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Schroder Investment Management Group cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 99.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,503 shares of the biopharmaceutical company’s stock after selling 9,933,836 shares during the quarter. Schroder Investment Management […] - 2025-04-06 08:30:52
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $62.78 Consensus Price Target from Analysts
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts […] - 2025-04-01 05:56:51
KLP Kapitalforvaltning AS Invests $1.25 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
KLP Kapitalforvaltning AS acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,253,000. Several other institutional investors […] - 2025-03-30 08:40:56
Xponance Inc. Grows Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Xponance Inc. raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,454 shares of the biopharmaceutical company’s stock after buying an additional 1,051 shares during the quarter. […] - 2025-03-25 09:42:57
Envestnet Portfolio Solutions Inc. Sells 446 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,435 shares of the biopharmaceutical company’s stock after selling 446 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in […] - 2025-03-24 08:22:47
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price at $62.78
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have been given an average rating of “Moderate Buy” by the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The […] - 2025-03-07 06:58:57
Private Advisor Group LLC Acquires 5,745 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Private Advisor Group LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 23.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,908 shares of the biopharmaceutical company’s stock after purchasing an additional 5,745 shares during the quarter. […] - 2025-02-27 09:11:06
Yousif Capital Management LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Yousif Capital Management LLC lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 4.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,169 shares of the biopharmaceutical company’s stock after selling 1,977 shares during the quarter. Yousif […] - 2025-02-11 08:40:55
Jennison Associates LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Jennison Associates LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,291 shares of the biopharmaceutical company’s stock, valued at approximately $731,000. Other hedge funds have also […] - 2025-02-07 10:28:50
Heck Capital Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 605 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. A number of other institutional investors have also […] - 2025-02-04 09:01:01

HALO institutional holdings

The following institutional investment holdings of HALO have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 82,408USD 5,581,494
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 34,360USD 2,327,203
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 171,479USD 11,614,273
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 58,634USD 3,971,281
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 58,634USD 3,971,281 -3.6%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 309USD 20,929
Total =405,824 USD 27,486,461
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.